FDA rare pediatric disease designation and priority review vouchers

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Sources accessed 17 October 2026.

How the program works

The rare pediatric disease priority review voucher program aims to encourage drug development for rare pediatric diseases. A sponsor that receives approval for a drug or biologic for a rare pediatric disease may qualify for a voucher, which can be redeemed for priority review of a different product, or transferred or sold to another sponsor.^[1]

Before submitting its marketing application, a sponsor planning to request a voucher may ask FDA for rare pediatric disease designation, and should say whether it is also requesting orphan or fast track designation.^[1]

The 2026 update

FDA's page states that with the enactment of the Consolidated Appropriations Act, 2026 on 3 February 2026, the rare pediatric disease voucher program will sunset after 30 September 2029, and FDA may not award any vouchers under the program after that date. FDA notes the law does not set a separate deadline by which a drug must be designated.^[1]

What it means for children and families

The program is an incentive for companies. It does not give families access to a drug before approval, and the voucher does not change how the approved drug is supplied.

Once a pediatric rare-disease drug is FDA-approved, families abroad can ask the treating hospital to request it through the national named-patient or special access route if it is not registered. In Saudi Arabia, the SFDA rare disease framework points to the Named Patient Program and the Special Access Program for unregistered rare-disease medicines.^[2]

Many recent pediatric rare-disease approvals are gene or cell therapies, which are given only at qualified treatment centers. For those, the realistic route is often a referral to a center abroad.^[3]

How the voucher speeds up a different product

A priority review voucher entitles its holder to priority review of another application. Under priority review, FDA's goal is to act within 6 months, compared with 10 months under standard review.^{[1, 4]}

This is why vouchers can be sold between companies: the benefit is a faster review for whichever product the buyer chooses.

Questions to ask the treating specialist

• Is there an FDA-approved treatment for my child's exact diagnosis and age?
• Is it a medicine the hospital can request, or a gene therapy given at a center abroad?
• What tests does the US label require first?
• Which centers offer the treatment, and how long is their referral process?

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help families and treating doctors understand the route, prepare the documents the regulator or hospital asks for, arrange supply from the US once approval is in place, and keep everyone updated. We do not diagnose, prescribe or decide what a regulator approves.

We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them. Your coordination fee is quoted in writing for your case before you commit. No hidden charges. We give you a written timeline estimate for your case before you commit.

Sources for these answers: ^{[1, 2]}

Related

• Orphan drug designation
• Priority review vouchers
• Rare disease access for children
• All access pathways
• US expanded access (compassionate use)
• Named-patient access, explained
• Answers to common access questions

This page is general information, not medical or legal advice. It does not replace advice from your own doctor or the regulator.